Protagonist Therapeutics, Inc. — FY2020 Form 10-K Summary
Business context and reporting period
Clinical-stage biopharmaceutical company developing peptide-based therapeutics for hematologic, inflammatory and immunomodulatory diseases. The filing covers the fiscal year ended December 31, 2020; it is an annual report, not a quarterly filing.
- Lead asset: rusfertide (PTG-300), an injectable hepcidin mimetic in Phase 2 studies for polycythemia vera (PV) and hereditary hemochromatosis (HH).
- PN-943 entered a Phase 2 ulcerative colitis study in 2020. Janssen is collaborating on PTG-200 and second-generation IL-23R antagonists PN-235 and PN-232.
- The company had no approved products and no product-sales revenue.
Financial performance and liquidity
| Metric | FY2020 | FY2019 | Change |
|---|---|---|---|
| License and collaboration revenue | $28.6 million | $0.2 million | +$28.4 million |
| Research and development expense | $74.5 million | $65.0 million | +15% |
| General and administrative expense | $18.6 million | $15.7 million | +18% |
| Loss from operations | $(64.5) million | $(80.5) million | Improved $16.0 million |
| Net loss | $(66.2) million | $(77.2) million | Improved $11.0 million |
| Net loss per share | $(1.92) | $(2.98) | Improved |
| Cash used in operating activities | $(72.5) million | $(41.5) million | Use increased $31.0 million |
- Cash, cash equivalents and marketable securities totaled $307.8 million at December 31, 2020, compared with $133.0 million at December 31, 2019. Total cash, cash equivalents and restricted cash were $117.8 million.
- Accumulated deficit was $283.8 million.
- No long-term debt was outstanding at year-end. The company repaid a $10.0 million term loan in June 2020 and paid approximately $0.6 million in related prepayment and exit fees. One $20.0 million tranche remained available under the facility, subject to conditions.
- Financing activities provided $247.6 million, primarily from public offerings and ATM sales. Net proceeds included $105.3 million from a May offering, $107.6 million from a December offering and $41.9 million from ATM sales.
- Research and development spending increased mainly because of rusfertide, PN-943 and preclinical/second-generation research; PTG-200 spending declined due to timing of deliverables and cost-sharing arrangements.
Material changes versus the prior comparable period
- Revenue increased substantially because of cumulative percentage-of-completion adjustments and continued performance under the Janssen agreement. FY2020 revenue included $27.1 million from proportional performance and $1.5 million from additional services.
- Revenue remains collaboration-based and non-recurring in nature; the company has never generated product-sales revenue.
- Rusfertide development shifted toward PV and HH. Development for beta-thalassemia and myelodysplastic-syndrome-associated anemia was discontinued during the first half of 2020.
- PN-943 advanced into Phase 2 for ulcerative colitis. PN-235 entered Phase 1 in December 2020, while PN-232 remained in late preclinical development.
- The company raised substantial equity capital, increasing issued and outstanding shares from 27.2 million at year-end 2019 to 43.7 million at year-end 2020.
- A limited reduction in force affecting approximately 12% of employees was completed in the second quarter; related cash expenditures were approximately $0.3 million.
Guidance, outlook, risks and unusual items
- Management expected to complete rusfertide PV Phase 2 enrollment by mid-2021 and consult with regulators during the first half of 2021 regarding a registrational plan. Preliminary HH data were expected in the second half of 2021.
- PN-943 Phase 2 was expected to be completed in 2022, subject to COVID-19-related delays. The company suspended completion timing guidance for Janssen’s PTG-200 Phase 2 study because of pandemic uncertainty.
- Interim PV data from 18 patients showed that most patients eliminated therapeutic phlebotomies while maintaining hematocrit below 45%; reported adverse events were primarily injection-site reactions and bruising, with no significant adverse events observed in the interim dataset. These were preliminary, non-pivotal results.
- COVID-19 caused delays in clinical-trial enrollment and could continue to affect trial operations, manufacturing, supply chains, regulatory interactions and liquidity.
- The Janssen agreement provided a $5.0 million milestone payment in 2020, potential future milestones of up to approximately $1.0 billion in aggregate and tiered royalties ranging from mid-single digits to 10% on net sales, but future payments depend on development, regulatory and commercial success.
- The company is party to an arbitration proceeding with Zealand Pharma concerning potential milestone and royalty obligations related to rusfertide. If Zealand prevails, potential obligations could include up to $28.0 million in development and regulatory milestones, up to $100.0 million in sales milestones and a low-single-digit royalty; no liability was accrued because management assessed the loss probability as remote.
- Management stated that existing cash, cash equivalents, marketable securities and access to the term-loan facility were expected to fund operations for at least 12 months from the filing date, but substantial additional funding will be required for continued development and potential commercialization.
- Ernst & Young audited the 2020 financial statements; the company’s registered public accounting firm was not required to attest to internal control effectiveness because of its emerging-growth-company status. Management concluded that disclosure controls and internal control over financial reporting were effective.
Most important facts for investors to verify
- Whether rusfertide’s preliminary PV findings translate into statistically persuasive, durable results in larger and later-stage trials.
- Timing, design and regulatory acceptance of a potential rusfertide registrational program.
- COVID-19 effects on enrollment, trial completion dates and clinical-supply availability.
- Janssen’s continued development decisions, milestone eligibility, cost-sharing obligations and potential termination rights.
- Cash burn and the timing and terms of future financing, including dilution from additional equity issuance.
- Outcome and potential financial exposure from the Zealand arbitration.
- Patent scope, remaining exclusivity and third-party intellectual-property risks for rusfertide and the oral IBD candidates.
- Whether the $307.8 million liquidity figure includes sufficient funds for the company’s expanding clinical programs under updated operating assumptions.